EUVIMEDEUVIMED entdecken
Crossref

Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma

Wenjia Zhu, Xiaoyuan Li, Guoyang Zheng, Chunmei Bai, Zhigang Ji, Haiqiong Zhang, Haiqun Xing, Yushi Zhang, Li Huo iD

European Journal of Nuclear Medicine and Molecular Imaging · 2023-08 · 50 (10) · 3116-3125

DOI: 10.1007/s00259-023-06248-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 29.05.2023. Verfasst von Wenjia Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College …. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Carbonic Anhydrases. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences Initiative for Innovative Medicine, National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Clear cell renal cell carcinoma (ccRCC) highly expresses carbonic anhydrase IX (CAIX). The purpose of this study was to evaluate 68Ga-NY104, a small-molecule CAIX-targeting PET agent, in tumor models of ccRCC and patients diagnosed with confirmed, or suspicious, ccRCC. METHODS: The in vivo and ex vivo biodistribution of 68Ga-NY104 was investigated in CAIX-positive OS-RC-2 xenograft-bearing models. The binding of the tracer was further validated using autoradiography for human ccRCC samples. In addition, three patients with confirmed or suspicious ccRCC were studied. RESULTS: NY104 can be labeled with high radiochemical yield and purity. It quickly cleared through kidney with α-half-life of 0.15 h. Discernible uptake is noted in the heart, lung, liver, stomach, and kidney. The OS-RC-2 xenograft demonstrated intense uptake 5 min after injection and gradually increased until 3 h after injection with ID%/g of 29.29 ± 6.82. Significant binding was detected using autoradiography on sections of human ccRCC tumor. In the three patients studied, 68Ga-NY104 was well-tolerated and no adverse events were reported. Substantial accumulation was observed in both primary and metastatic lesions in patient 1 and 2 with SUVmax of 42.3. Uptake in the stomach, pancreas, intestine, and choroid plexus was noted. The lesion in third patient was correctly diagnosed as non-metastatic for negative 68Ga-NY104 uptake. CONCLUSION: 68Ga-NY104 can efficiently and specifically bind to CAIX. Given the pilot nature of our study, future clinical studies are warranted to evaluate 68Ga-NY104 for detection of CAIX-positive lesions in patients with ccRCC. TRIAL REGISTRATION: The clinical evaluation part of this study was retrospectively registered at ClinicalTrial.gov (NCT05728515) as NYPILOT on 6 Feb, 2023.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsCarbonic AnhydrasesHumansCarbonic Anhydrase IXTissue DistributionGallium RadioisotopesAntigens, NeoplasmPositron-Emission Tomography

Stichwörter der Autor:innen

68Ga-NY104Carbonic anhydrase IXClear cell renal cell carcinoma

Substanzen

Carbonic Anhydrase IXGallium RadioisotopesCarbonic AnhydrasesAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical…
  • Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
  • Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
  • Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. zhangyushi@126.com.

ORCID-Profile: Li Huo

Förderung

  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine
  • National Natural Science Foundation of China
  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Zhu, W., Li, X., Zheng, G., Bai, C., Ji, Z., Zhang, H., Xing, H., Zhang, Y., & Huo, L. (2023). Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 50(10), 3116-3125. https://doi.org/10.1007/s00259-023-06248-7

Vancouver

Zhu W, Li X, Zheng G, Bai C, Ji Z, Zhang H, et al. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2023;50(10):3116-3125. doi:10.1007/s00259-023-06248-7

BibTeX
@article{Zhu2023,
  author = {Zhu, Wenjia and Li, Xiaoyuan and Zheng, Guoyang and Bai, Chunmei and Ji, Zhigang and Zhang, Haiqiong and Xing, Haiqun and Zhang, Yushi and Huo, Li},
  title = {Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2023},
  volume = {50},
  number = {10},
  pages = {3116--3125},
  doi = {10.1007/s00259-023-06248-7}
}
Kostenlos starten →